SPAQ-CO™ dispersible

Guilin, a Fosum Pharma company

Product category
  • Intermittent preventive treatment (sulfadoxine-pyrimethamine + amodiaquine)
Therapeutic indication
  • Seasonal malaria chemoprevention (SMC) for children 3 to 59 months in eligible regions (Sahel region in sub-Saharan Africa)

Dosing
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months

Efficacy
  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Three-year shelf life
Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • >500 million treatments distributed since launch in 2014
  • First taste-masked dispersible SPAQ formulation prequalified by WHO
Next milestone
  • Extension of the recommendation for children up to their 10th birthday
  • Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday
  • Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
  • Confirmation of potential efficacy and adoption in areas outside of the Sahel region
MMV Project Director
  • Dr André-Marie Tchouatieu